Triple-negative breast cancer is a subtype of invasive breast cancer， accounting for about 15% of all breast cancers. Its clinical treatment is relatively difficult， prone to recurrence and metastasis， with a short median survival and poor prognosis. Sacituzumab govitecan is the first approved antigen-coupled drug targeting trophoblast surface antigen 2 in the world. It has significant clinical efficacy， high safety and less adverse reactions， which brings new hope to the treatment of triple-negative breast cancer.